en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The combination of radiotherapy and surgery is used to treat locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to analyze IIIA/B NSCLC patients treated with chemotherapy from the Surveillance, Epidemiology, and End Results (SEER) database to clarify whether patient prognosis correlated with surgery and radiotherapy. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The IIIA/B NSCLC patients were selected from the SEER database and classified into IIIA (N0-1), IIIA (N2), IIIB (N2), and IIIB (N3). Cox analyses and Kaplan&ndash;Meier method were used to estimate the prognostic factors and lung cancer specific survival (LCSS) curves. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">We divided 7933 cases into IIIA (N0-1), IIIA (N2), IIIB (N2), and IIIB (N3). Cox regression showed that age, sex, primary site, grade, treatment, T stage, and marriage were independent risk factors for IIIA (N0-1); age, sex, treatment, and T stage had prognostic significance for IIIA (N2); age, sex, primary site, grade, treatment, and T stage were prognostic factors for IIIB (N2); and age and primary site had effect on the prognosis of IIIB(N3). The&nbsp;effect of chemotherapy-surgery was better than that of chemotherapy-preoperative radiotherapy-surgery and chemotherapy-surgery-postoperative radiotherapy for IIIA (N0-1). In IIIA (N2) and IIIB, radiotherapy did not improve the LCSS. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Surgery offered more survival benefits for IIIA (N0-1) patients. Radiotherapy did not improve the LCSS of IIIA (N2) and IIIB patients.</span></span></span></span></span></span></span></span></span></div> Surgery, radiotherapy, NSCLC, prognosis, chemotherapy. 475 483 http://ijrr.com/browse.php?a_code=A-10-1-1069&slc_lang=en&sid=1 Y. Zeng 7900319475328460024244 7900319475328460024244 No Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China G. Wang 7900319475328460024245 7900319475328460024245 No Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China H. Zheng 7900319475328460024246 7900319475328460024246 No Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China Y. Wang 7900319475328460024247 7900319475328460024247 No Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China G. Ma 7900319475328460024248 7900319475328460024248 No Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China Z. Pang 7900319475328460024249 7900319475328460024249 No Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China J. Du dujiajun@sdu.edu.cn 7900319475328460024250 7900319475328460024250 Yes Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China